Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.48 |
| ▸ | MERTK | Q12866 | 1/20 | 0.48 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185546 | 0.84 | MAPT (0.61) | MAPTPOLBPKMALDH1A1KDM4E | |
| SCHEMBL3577968 | 0.80 | EGFR (0.52) | MAPTPOLBPKMALDH1A1LMNA | |
| SCHEMBL2943473 | 0.80 | TYRO3 (0.50) | MAPTPOLBPKMALDH1A1HTT | |
| SCHEMBL2376571 | 0.79 | MAPT (0.68) | MAPTPOLBPKMALDH1A1HTT | |
| SCHEMBL2944003 | 0.78 | LCK (0.63) | MAPTPOLBPKMALDH1A1HTT | |
| SCHEMBL14454203 | 0.77 | TYRO3 (0.51) | MAPTPOLBPKMALDH1A1HTT | |
| SCHEMBL28372825 | 0.77 | KDM4E (0.54) | ALDH1A1LMNAKDM4ESMN1; SMN2GAA | |
| SCHEMBL29953666 | 0.76 | TYRO3 (0.50) | MAPTPOLBPKMALDH1A1LMNA | |
| SCHEMBL11988204 | 0.76 | TYRO3 (0.50) | MAPTPOLBPKMALDH1A1LMNA | |
| SCHEMBL6152689 | 0.76 | PKM (0.56) | MAPTPOLBPKMALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928844-B1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8492404-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1928844-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007022380-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | LCK, BTK, IRAK1 | MAPT 4311/4885POLB 3447/4885PKM 358/4885 |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | LCK, BTK, IRAK1 | MAPT 4311/4885POLB 3447/4885PKM 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.